On January 27, 2022 LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, reported to offer for the second time two lung cancer research award programs to support early-stage lung cancer researchers from underrepresented populations in the biomedical research workforce (Press release, LUNGevity Foundation, JAN 27, 2022, View Source [SID1234607462]). These awards, to be granted in 2022, are in addition to LUNGevity’s 2022 Career Development Awards.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The 2022 LUNGevity Health Equity and Inclusiveness Research Fellow Award program supports fellows interested in translational lung cancer research who belong to underrepresented minorities in STEM, as per the National Science Foundation. Applicants must hold a doctoral degree, be within the first or second year of their fellowship, and plan to pursue a lung cancer research career. This is a mentored award, which may be for a maximum of $100,000 over two years ($50,000 per year).
The 2022 LUNGevity Health Equity and Inclusiveness Junior Investigator Award program supports physician-scientists interested in conducting lung cancer clinical research. Applicants must hold a doctoral degree, be within the first five years of their first faculty appointment, and have completed a training fellowship. This is a mentored award, which may be for a maximum of $200,000 over two years ($100,000 per year).
"Healthcare inequity is a long-standing problem for underserved communities," explained Robert A. Winn, MD, director of Virginia Commonwealth University Massey Cancer Center and LUNGevity board member. "Lack of ethnic and racial minority clinicians and researchers exacerbates the issue. Programs like the LUNGevity HEI Awards that increase access to clinicians who understand the unique needs of underserved communities are a means to bridging the inequity gap."
Projects funded in 2022 are expected to have a direct impact on the early detection of lung cancer or the outcomes of lung cancer or to provide a clear conceptual or experimental foundation for the future development of methods of early detection and/or individualized treatment, including through targeted therapy and immunotherapy.
The RFAs for these awards are available on the LUNGevity website at LUNGevity.org/apply-for-award and the ProposalCentral website at proposalcentral.com.
"LUNGevity is proud to fund these awards to establish more diverse voices in the lung cancer workforce," stated LUNGevity CEO Andrea Ferris.
Letters of intent for both awards must be submitted by February 23, 2022.